Aprogen Pharmaceuticals Inc (003060.KS)
Aprogen Biologics Inc. manufactures and sells pharmaceutical products primarily in South Korea. It offers approximately 200 types of medicines, including ethical and over the counter drugs. The company offers its drugs for transfusion, digestive system, osteoarthritis, skeletal muscle relaxants, NSAIDs, osteoporosis, circulatory system, endocrine, respiratory system, urinary system, depilatory, antihistamines and antiallergics, obesity, brain function, neurologics, and male pattern hair loss. It also provides anti-biotic, anti-fungal, anti-viral, anti-ulcerant, anti-epliepsy products; external agents; anti-cancer drugs; amino-acid nutrient transfusion agents; and cosmetics. Aprogen Biologics Inc. was founded in 1960 and is headquartered in Seongnam-si, South Korea.
Company Info
Highlights
₩130.00B
₩51.77B
-₩8.53B
₩600.00 - ₩1,780.00
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
Loading data...
Returns By Period
Aprogen Pharmaceuticals Inc (003060.KS) returned -0.60% year-to-date (YTD) and -45.08% over the past 12 months. Over the past 10 years, 003060.KS returned -21.95% annually, underperforming the S&P 500 benchmark at 10.85%.
003060.KS
-0.60%
-5.05%
-9.86%
-45.08%
-49.49%
-45.26%
-21.95%
^GSPC (Benchmark)
0.51%
3.96%
-2.00%
12.02%
12.68%
14.19%
10.85%
Monthly Returns
The table below presents the monthly returns of 003060.KS, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | 14.80% | -3.42% | 0.82% | -5.95% | -5.46% | -0.60% | |||||||
| 2024 | -36.90% | -7.65% | 12.43% | -16.11% | -1.10% | -16.11% | 13.73% | -7.79% | -13.28% | -11.38% | -9.88% | -9.32% | -69.96% |
| 2023 | -27.24% | -2.73% | 2.53% | 3.29% | 8.49% | -5.87% | -4.42% | 30.43% | -22.71% | -12.13% | -8.59% | -2.68% | -42.35% |
| 2022 | -18.45% | 6.78% | 4.19% | -1.22% | -17.14% | -11.90% | 13.51% | -9.82% | -20.63% | 15.38% | -8.83% | -0.59% | -44.42% |
| 2021 | -12.55% | -2.17% | 4.00% | 1.71% | 1.68% | 2.07% | -2.83% | -5.83% | -6.64% | -3.32% | -17.55% | 7.61% | -31.18% |
| 2020 | -3.32% | 17.18% | 9.12% | 25.37% | -4.76% | 5.01% | -17.30% | 2.29% | -17.89% | -2.72% | 12.40% | -6.41% | 10.17% |
| 2019 | 2.31% | 0.41% | -10.41% | 20.05% | -29.98% | -11.20% | -30.52% | -9.25% | -9.68% | 57.97% | -0.89% | 22.07% | -25.24% |
| 2018 | 7.68% | -2.49% | -1.28% | -2.94% | -4.48% | -3.93% | -11.76% | 20.36% | -7.71% | -29.65% | 8.05% | -15.43% | -41.83% |
| 2017 | -10.86% | 6.30% | -9.70% | 12.84% | 1.19% | 5.23% | 1.24% | -3.44% | 0.38% | -6.71% | 22.39% | -9.09% | 4.73% |
| 2016 | 41.50% | -3.31% | 0.80% | 26.70% | 28.57% | -17.92% | 11.34% | -28.57% | 10.43% | -27.36% | -3.45% | 7.55% | 22.15% |
| 2015 | 60.24% | -26.79% | 38.05% | 1.36% | -13.22% | 45.21% | 200.71% | 26.47% | -47.44% | 12.68% | -1.83% | -14.53% | 290.85% |
| 2014 | 8.91% | -11.98% | -0.91% | -3.89% | -3.57% | -1.23% | 8.75% | 16.09% | 5.94% | -9.53% | -13.64% | -1.91% | -10.87% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of 003060.KS is 13, meaning it’s performing worse than 87% of other stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Aprogen Pharmaceuticals Inc (003060.KS) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Loading data...
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading data...
Worst Drawdowns
The table below displays the maximum drawdowns of the Aprogen Pharmaceuticals Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Aprogen Pharmaceuticals Inc was 99.94%, occurring on May 20, 2025. The portfolio has not yet recovered.
The current Aprogen Pharmaceuticals Inc drawdown is 99.93%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -99.94% | Jan 9, 2001 | 5865 | May 20, 2025 | — | — | — |
| -79.18% | Jan 19, 1998 | 92 | Jul 7, 1998 | 123 | Jan 18, 1999 | 215 |
| -72.71% | Feb 3, 1999 | 359 | Jul 24, 2000 | 27 | Sep 1, 2000 | 386 |
| -35.01% | Dec 1, 1997 | 9 | Dec 15, 1997 | 8 | Jan 5, 1998 | 17 |
| -34.69% | Oct 13, 2000 | 13 | Oct 31, 2000 | 5 | Nov 7, 2000 | 18 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading data...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Aprogen Pharmaceuticals Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Earnings Per Share
The chart presents the Earnings Per Share (EPS) performance of Aprogen Pharmaceuticals Inc, comparing actual results with analytics estimates.
Valuation
The Valuation section provides an overview of how Aprogen Pharmaceuticals Inc is priced in the market compared to other companies in the Drug Manufacturers - Specialty & Generic industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for 003060.KS compared to other companies in the Drug Manufacturers - Specialty & Generic industry. 003060.KS currently has a PEG ratio of 0.0. This PEG ratio is low compared to industry peers, which could indicate the stock is undervalued relative to its expected growth.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for 003060.KS relative to other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, 003060.KS has a P/S ratio of 1.9. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for 003060.KS in comparison with other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, 003060.KS has a P/B value of 0.4. This P/B ratio is low compared to industry peers. It might indicate the stock is undervalued or that the company’s assets are not expected to generate strong returns.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |